Product Pipeline
Therapeutic Areas
R&D Strategy

R&D Strategy

The new drug development approach undertaken by Asieris Pharmaceuticals is distinct from the traditional approach. Through internal research or collaboration with leading research institutions, we purposefully identify old drugs with new clinical experience and/or with new anti-tumor mechanism of actions. These drugs become our first-generation products, allowing us to rapidly progress them into proof-of-concept clinical trials. Meanwhile, we innovate upon these first-generation products by improving their efficacy, safety, or broadening their anti-tumor indications.  

This approach shortens the timelines by several years for our first-generation products to enter clinical development and to reach market, and at the same time greatly reduce the development risks associated with the safety and toxicity of a new drug. Our second-generation products are improved versions based on the clinical research experience of the first-generation products, thereby mitigating the safety and efficacy risks associated with new drug targets.
Successful cases of such research and development approach already exist. 

Thalidomide was originally used for the treatment of nausea and vomiting in pregnant women, and was pulled out of the market in 1960 because it would cause malformation in newborns. Later research revealed that it had effects in the treatment of leprosy, AIDS and tumors. 

In 1998, the United States biopharmaceutical company Celgene gained approval to market thalidomide for the treatment of leprosy, and later also gained approval for multiple myeloma.

The second-generation product Lenalidomide, also developed by Celgene, gained approval to enter the market in year 2006, to be used in the treatment of multiple myeloma. The global sale of
Lenalidomide and the third-generation pomalidomide in year 2014 was nearly 5 billion US dollars, and is expected to reach $10 billion dollars in year 2020.

At present, the new drug APL-1202, developed by Asieris Pharmaceuticals for the treatment of non-muscle-invasive bladder cancer, has showed superior safety in early clinical use. While APL-1202 is under clinical research, Asieris Pharmaceuticals is also developing its second-generation product, which is expected to be superior to APL-1202 in clinical efficacy. In the meantime, several other drug projects are also being conducted by Asieris Pharmaceuticals for the treatment of other later-stage malignant tumors.